as02
Small moleculeexperimental
Clinical trial activity
10 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2001 (NCT01556945)
Timeline
Indications
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- as02
- as02a
- as02d
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00289185 | Phase 2 | Sep 27, 2006 | GlaxoSmithKline |
| NCT00385047 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2006 | GlaxoSmithKline, PATH, United States Agency for International Development, United States Army |
| NCT00312702 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2006 | GlaxoSmithKline, PATH, United States Army |
| NCT00197028 | Phase 2 | Aug 23, 2005 | GlaxoSmithKline |
| NCT00197054 | Phase 2 | Jul 1, 2005 | GlaxoSmithKline, United States Army |
| NCT00197067 | Phase 1 | Mar 15, 2004 | GlaxoSmithKline |
| NCT00075049 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2003 | GlaxoSmithKline, United States Army |
| NCT00197041 | Phase 2 | Jul 1, 2003 | GlaxoSmithKline |
| NCT00027365 | Phase 1 | Dec 4, 2001 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01556945 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2001 | GlaxoSmithKline, United States Army |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 9 | 4 | 2 | 2001 |
| United States Army | Government | 5 | 5 | 1 | 2001 |
| PATH | Academic/Hospital | 2 | 0 | 1 | 2006 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2001 |
| United States Agency for International Development | Government | 1 | 0 | 1 | 2006 |
5 organizations
Page 1 / 1